Literature DB >> 25667026

Prokinetics in gastroparesis.

Andres Acosta1, Michael Camilleri2.   

Abstract

Prokinetic agents are medications that enhance coordinated gastrointestinal motility and transit of content in the gastrointestinal tract, mainly by amplifying and coordinating the gastrointestinal muscular contractions. In addition to dietary therapy, prokinetic therapy should be considered as a means to improve gastric emptying and symptoms of gastroparesis, balancing benefits and risks of treatment. In the United States, metoclopramide remains the first-line prokinetic therapy, because it is the only approved medication for gastroparesis. Newer agents are being developed for the management of gastroparesis. This article provides detailed information about prokinetic agents for the treatment of gastroparesis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Domperidone; Erythromycin; Ghrelin; Metoclopramide; Pharmacology; Pyridostigmine; Receptor; Relamorelin; Serotonin

Mesh:

Substances:

Year:  2014        PMID: 25667026     DOI: 10.1016/j.gtc.2014.11.008

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  23 in total

Review 1.  Childhood gastroparesis is a unique entity in need of further investigation.

Authors:  Liz Febo-Rodriguez; Bruno P Chumpitazi; Robert J Shulman
Journal:  Neurogastroenterol Motil       Date:  2019-08-13       Impact factor: 3.598

Review 2.  Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

Authors:  Tracy M Frech; Diane Mar
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

Review 3.  Gastric Peroral Endoscopic Pyloromyotomy Therapy for Refractory Gastroparesis.

Authors:  Petros C Benias; Mouen A Khashab
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

4.  Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine.

Authors:  Zeljka Belosic Halle; Josipa Vlainic; Domagoj Drmic; Dean Strinic; Kresimir Luetic; Mario Sucic; Maria Medvidovic-Grubisic; Tatjana Pavelic Turudic; Igor Petrovic; Sven Seiwerth; Predrag Sikiric
Journal:  Inflammopharmacology       Date:  2017-05-17       Impact factor: 4.473

Review 5.  Prokinetics in the Management of Functional Gastrointestinal Disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2017-09-08

6.  Current and Emerging Medical Therapies for Gastroparesis.

Authors:  Xiaofeng Zhao; Hiroshi Mashimo
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12

Review 7.  Parkinson's Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects.

Authors:  Chethan Ramprasad; Jane Yellowlees Douglas; Baharak Moshiree
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 8.  Functional dyspepsia: new insights into pathogenesis and therapy.

Authors:  Nicholas J Talley
Journal:  Korean J Intern Med       Date:  2016-04-06       Impact factor: 2.884

Review 9.  The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials.

Authors:  Kim Lewis; Zuhoor Alqahtani; Lauralyn Mcintyre; Saleh Almenawer; Fayez Alshamsi; Andrew Rhodes; Laura Evans; Derek C Angus; Waleed Alhazzani
Journal:  Crit Care       Date:  2016-08-15       Impact factor: 9.097

Review 10.  A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.

Authors:  Sheena K Aurora; Stephen B Shrewsbury; Sutapa Ray; Nada Hindiyeh; Linda Nguyen
Journal:  Headache       Date:  2021-04-01       Impact factor: 5.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.